Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for RASBURICASE
- Rasburicase Treatment in Chronic Gouty Arthritis
- Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
- Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia
- The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma
- Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
- Uric Acid Effects on Endothelium and Oxydative Stress
- Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
- Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status
- Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
- The Relationship Between Uric Acid and Inflammatory Markers
- Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
- Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia
- Lowering Serum Uric Acid to Prevent Acute Kidney Injury
- Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma
- Fasturtec TLS Treatment / Prophylysis
- Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma
- Rasburicase in Patients at Risk for Tumor Lysis Syndrome
- Rasburicase (Fasturtec) Registration Trial
- Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
- Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
- Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
- Rasburicase in Tumor Lysis Syndrome
- Rasburicase for Hyperuricemia
- Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
- Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
- Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
- Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
- Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Clinical trials list
click for details